EGFR and pulmonary fibrosis: Although an assessment of pulmonary comorbidities, especially ILDs, is important to decrease the incidence of ILD induced by chemotherapy, the frequency of EGFR mutation in patients with pulmonary fibrosis and the clinical feature of these patients are not clear.